Trinity Biotech PLC (NASDAQ:TRIB – Get Free Report) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totaling 17,870 shares, a growth of 123.3% from the September 15th total of 8,001 shares. Based on an average daily trading volume, of 8,408 shares, the days-to-cover ratio is presently 2.1 days. Approximately 2.4% of the shares of the stock are short sold.
Trinity Biotech Trading Up 7.2%
Shares of NASDAQ TRIB opened at $6.75 on Wednesday. The stock has a market capitalization of $5.47 million, a PE ratio of -0.15 and a beta of 0.73. Trinity Biotech has a twelve month low of $5.01 and a twelve month high of $52.50. The stock has a fifty day simple moving average of $8.81 and a 200-day simple moving average of $13.85.
Institutional Trading of Trinity Biotech
A hedge fund recently raised its position in Trinity Biotech stock. Williams & Novak LLC increased its stake in shares of Trinity Biotech PLC (NASDAQ:TRIB – Free Report) by 30.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 140,543 shares of the company’s stock after buying an additional 32,900 shares during the quarter. Williams & Novak LLC owned about 3.91% of Trinity Biotech worth $55,000 at the end of the most recent quarter. Institutional investors and hedge funds own 78.97% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Report on TRIB
Trinity Biotech Company Profile
Trinity Biotech plc is a biotechnology and medical diagnostics company headquartered in Bray, Ireland. The company develops, manufactures and markets diagnostic products used by clinical laboratories, healthcare professionals and patients.
Its product portfolio includes tests for infectious diseases, autoimmune disorders and diabetes. Trinity Biotech is particularly known for HIV diagnostic products, including rapid and laboratory-based testing solutions, as well as assays and instruments used in clinical testing.
Read More
- Five stocks we like better than Trinity Biotech
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
- PepsiCo’s Earnings Beat Masks a Bigger Problem With Its North American Business
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
